Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Cotinga Pharmaceuticals Inc. (OTC: COTQF).

Full DD Report for COTQF

You must become a subscriber to view this report.


Recent News from (OTC: COTQF)

Cotinga Pharmaceuticals Reports Fiscal 2018 Fourth Quarter and Full Year Financial and Operating Results
TORONTO and BOSTON, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT; OTCQB: COTQF) (“Cotinga” or the “Company”) , a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, r...
Source: GlobeNewswire
Date: August, 29 2018 08:00
Cotinga Pharmaceuticals Announces Management and Board Changes
LONDON, Ontario and BOSTON, July 02, 2018 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture:COT) (OTCQB:COTQF) (“Cotinga” or the “Company”) , a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of ca...
Source: GlobeNewswire
Date: July, 02 2018 16:30
Your Daily Pharma Scoop: ACRX NDA Accepted, BioMarin Gets Approval, Genmab Fails Study
Analysis Focus: ACRX AcelRX (ACRX), as I have repeatedly noted, is a trader’s dream stock. It moves from plateau to plateau, but while in each plateau, it keeps itself extremely range-bound - therefore predictable. That predictability was shattered only once - if you look at its one...
Source: SeekingAlpha
Date: May, 27 2018 19:15
Continga Pharma changes study protocol for lead drug COTI-2, will evaluate in combination with chemo
Cotinga Pharmaceuticals ( OTCQB:COTQF ) announces that the FDA has signed off on a protocol amendment to its Phase 1/2 clinical trial evaluating lead candidate COTI-2 in a range of cancers. More news on: Cotinga Pharmaceuticals Inc., Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 24 2018 11:32
Cotinga Pharmaceuticals Announces FDA Clearance of Significant Protocol Changes for COTI-2 Clinical Program
LONDON, Ontario and BOSTON, May 24, 2018 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX-V:COT) (OTCQB:COTQF) (“Cotinga” or the “Company”) , a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, t...
Source: GlobeNewswire
Date: May, 24 2018 08:00
Cotinga Pharmaceuticals Announces Presentation on COTI-2 at the 2018 American Society of Clinical Oncology Annual Meeting
LONDON, Ontario and BOSTON, May 17, 2018 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture:COT) (OTCQB:COTQF) (“Cotinga” or the “Company”) , a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of can...
Source: GlobeNewswire
Date: May, 17 2018 07:30
Cotinga Pharmaceuticals Closes $2.0M Private Placement
LONDON and BOSTON, May 04, 2018 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture:COT) (OTCQB:COTQF) (“Cotinga” or the “Company”) , a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, toda...
Source: GlobeNewswire
Date: May, 04 2018 08:00
Cotinga Pharmaceuticals Reports Fiscal 2018 Third Quarter Financial and Operating Results
LONDON, Ontario and BOSTON, April 03, 2018 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture:COT) (OTCQB:COTQF) (“Cotinga” or the “Company”) , a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of c...
Source: GlobeNewswire
Date: April, 03 2018 17:00
Cotinga Pharmaceuticals Announces Presentation on COTI-2 at the American Association for Cancer Research (AACR) Annual Meeting 2018
LONDON, Ontario and BOSTON, April 03, 2018 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture:COT) (OTCQB:COTQF) (“Cotinga” or the “Company”) , a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of c...
Source: GlobeNewswire
Date: April, 03 2018 08:00
Cotinga Pharmaceuticals Provides Update on COTI-2 Clinical Programs
LONDON, Ontario and BOSTON, March 20, 2018 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture:COT) (OTCQB:COTQF) (“Cotinga” or the “Company”) , a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment...
Source: GlobeNewswire
Date: March, 20 2018 07:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-07N/A0.04575N/AN/A0
2018-12-06N/A0.04575N/AN/A0
2018-12-05N/A0.04575N/AN/A0
2018-12-04N/A0.04575N/AN/A0
2018-12-030.04050.045750.045750.04055,750

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-11-207,0007,000100.0000Short
2018-11-165,0005,000100.0000Short
2018-11-0530,00030,000100.0000Short
2018-11-023001,10027.2727Cover
2018-10-162,5002,500100.0000Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on COTQF.


About Cotinga Pharmaceuticals Inc. (OTC: COTQF)

Logo for Cotinga Pharmaceuticals Inc. (OTC: COTQF)

COTI is a clinical stage biotech company that uses proprietary artificial intelligence technologies to pursue a targeted and transformational approach to treating cancer and other unmet medical needs. The Company s lead compound, COTI , has a novel p dependent mechanism of action with selective and potent anti cancer activity. COTI is initially being evaluated for the treatment of gynecologic cancers and head and neck squamous cell carcinoma in a Phase clinical trial at the MD Anderson Cancer Center. The Company has secured orphan drug status for the treatment of ovarian cancer in the U.S. Pre clinical data suggests that COTI could dramatically improve the treatment of cancers with mutations in the p gene.

 

 

 

Current Management

  • Alison Denise Silva / CEO
  • Gene Francis Kelly / CFO
  • John Drake / Chairman, Independent Director, Audit Committee Member, Compensation Committee Member
  • Douglas Alexander / Independent Director, Audit Committee Member
  • David Sanderson / Audit Committee Member
  • Alison Denise Silva /
  • John Yoo / Independent Director

Current Share Structure

  • Market Cap: $8,022,675 - 03/09/2018
  • Issue and Outstanding: 16,696,515 - 02/22/2018
  • Float: 15,258,620 - 02/22/2018

 


Recent Filings from (OTC: COTQF)

Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act
Filing Type: DFiling Source: edgar
Filing Date: May, 15 2018
Articles of Incorporation - Articles of Amendment - Name Change
Filing Type: Articles of Incorporation - Articles of Amendment - Name ChangeFiling Source: OTC Markets
Filing Date: January, 09 2018
Interim Financial Report - Certificate of Interim Filings - CFO
Filing Type: Interim Financial Report - Certificate of Interim Filings - CFOFiling Source: OTC Markets
Filing Date: December, 29 2017
Interim Financial Report - Certificate of Interim Filings - CEO
Filing Type: Interim Financial Report - Certificate of Interim Filings - CEOFiling Source: OTC Markets
Filing Date: December, 29 2017
Interim Financial Report - Management Discussion and Analysis Oct 31/17
Filing Type: Interim Financial Report - Management Discussion and Analysis Oct 31/17Filing Source: OTC Markets
Filing Date: December, 29 2017
Interim Financial Report - Interim Financial Statements Oct 31/17
Filing Type: Interim Financial Report - Interim Financial Statements Oct 31/17Filing Source: OTC Markets
Filing Date: December, 29 2017
OTCQB Certification - OTCQB Certification
Filing Type: OTCQB Certification - OTCQB CertificationFiling Source: OTC Markets
Filing Date: December, 13 2017
Interim Financial Report - Certificate of Interim Filings Chief Financial Officer July 31, 2017
Filing Type: Interim Financial Report - Certificate of Interim Filings Chief Financial Officer July 31, 2017Filing Source: OTC Markets
Filing Date: October, 02 2017
Interim Financial Report - Certificate of Interim Filings Chief Executive Officer July 31/17
Filing Type: Interim Financial Report - Certificate of Interim Filings Chief Executive Officer July 31/17Filing Source: OTC Markets
Filing Date: October, 02 2017
Management Discussion and Analysis - Interim MD&A July 31/17
Filing Type: Management Discussion and Analysis - Interim MD&A July 31/17Filing Source: OTC Markets
Filing Date: October, 02 2017

 

 


Daily Technical Chart for (OTC: COTQF)

Daily Technical Chart for (OTC: COTQF)


Stay tuned for daily updates and more on (OTC: COTQF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: COTQF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in COTQF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of COTQF and does not buy, sell, or trade any shares of COTQF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/